Literature DB >> 9508350

The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades.

F Cervantes1, A Pereira, J Esteve, F Cobo, C Rozman, E Montserrat.   

Abstract

In an attempt to ascertain whether the presenting features of idiopathic myelofibrosis (IM) have changed in recent years, 2 groups of patients diagnosed with IM in a single institution in different time periods were compared. The first group included 53 patients diagnosed from 1975 to 1986, and the second included 56 patients diagnosed from 1987 to 1997. No significant differences were observed between the two groups with regard to age, gender, delay from first symptoms to disease diagnosis, peripheral blood hematological values and serum biochemical parameters. Patients diagnosed prior to 1987 presented more often with constitutional symptoms (fever, night sweats, weight loss), but the difference did not reach statistical significance. These latter patients had, however, a higher frequency of splenomegaly (91% vs. 73%, p=0.01) and hepatomegaly (79% vs. 48%, p=0.002), and were more often in the osteosclerotic phase at diagnosis (p=0.05) than patients more recently diagnosed. Finally, no significant differences were found between both groups in either the distribution by prognostic scores or survival. The above results seem to indicate a trend towards a less florid clinical picture of IM at presentation in recent years. This, however, does not result in a longer patient survival.

Entities:  

Mesh:

Year:  1998        PMID: 9508350     DOI: 10.1111/j.1600-0609.1998.tb01005.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  1 in total

1.  Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years.

Authors:  Rakhee Vaidya; Sergio Siragusa; Jocelin Huang; Susan M Schwager; Curtis A Hanson; Kebede Hussein; Animesh Pardanani; Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.